CoChat

Cyclin D as a therapeutic target in cancer

The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.

Abstract

Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc3090

Cites

191 of 191 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 1,370

Metadata

Authors
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
Affiliations
Garvan Institute of Medical Research (AU)
Corresponding author
Sutherland, Robert L.
Venue
Nature Reviews Cancer
Published
2011-07-07
Volume
11
Issue
8
Pages
558-572
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2089655089
Cited by
1,370
References
190
Citations by year
2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
FWCI
7.64
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
MeSH terms
Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.